Key Takeaways
- • Clair Health closed an $11.6 million seed funding round led by Khosla Ventures to commercialize the first noninvasive, continuous hormone monitor for women, with product launch targeted for November 2026.
- • The device employs 10 biosensors and monitors 130+ biomarkers to track estrogen, progesterone, LH, and FSH in real time without blood draws, addressing a gap in existing wearable offerings from competitors including Oura, WHOOP, and Apple.
- • Early clinical data identified nine distinct sub-phases within the female hormone cycle, contradicting the traditional four-phase model and suggesting significant opportunity for differentiation in the $96 billion wearable market.
- • Co-founders Jenny Duan and Abhinav Agarwal met at Stanford in spring 2025; Duan's research into clinical trial history revealed that women were not required in US clinical trials until 1993, informing the company's mission to address women's health monitoring gaps.
- • The funding syndicate included a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki, alongside lead investor Khosla Ventures, signaling institutional confidence in women's health wearable technology.
Summary
Clair Health, a San Francisco-based startup founded by 21-year-old Jenny Duan and Abhinav Agarwal, has secured $11.6 million in seed funding led by Khosla Ventures to develop and commercialize a continuous hormone monitoring device for women. The company plans to launch its noninvasive product in November 2026, targeting what industry observers describe as a significant blind spot in the $96 billion wearable technology market.
The device addresses a fundamental limitation in existing wearable platforms. While established competitors like Oura, WHOOP, and Apple monitor sleep, heart rate variability, and daily step counts, they operate on the assumption that the female body functions consistently across all days of the cycle. Clair's technology uses 10 biosensors and more than 130 biomarkers to track four primary hormones—estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH)—in real time without requiring blood draws or needle insertion. Early testing has identified nine distinct sub-phases within the female hormone cycle, challenging the long-standing four-phase clinical model and suggesting substantial room for product differentiation and clinical validation.
Duan's motivation stems from academic research conducted during her undergraduate years at Stanford, where she discovered that women were not mandated to participate in US clinical trials until 1993. She also experienced firsthand the limitations of existing cycle-tracking applications, which did not adequately represent her own irregular cycle patterns. This observation, combined with her co-founder Agarwal, led to Clair Health's formation in spring 2025 and the subsequent capital raise.
The funding round reflects strong institutional backing beyond Khosla Ventures, with participation from a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and investor Anne Wojcicki. Khosla Ventures' involvement carries particular weight given the firm's track record backing high-impact consumer and technology companies including DoorDash, Affirm, and Okta. The syndicate composition suggests confidence in both the market opportunity and the founding team's ability to execute a meaningful shift in how women's health data is monitored at scale.
The device addresses a fundamental limitation in existing wearable platforms. While established competitors like Oura, WHOOP, and Apple monitor sleep, heart rate variability, and daily step counts, they operate on the assumption that the female body functions consistently across all days of the cycle. Clair's technology uses 10 biosensors and more than 130 biomarkers to track four primary hormones—estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH)—in real time without requiring blood draws or needle insertion. Early testing has identified nine distinct sub-phases within the female hormone cycle, challenging the long-standing four-phase clinical model and suggesting substantial room for product differentiation and clinical validation.
Duan's motivation stems from academic research conducted during her undergraduate years at Stanford, where she discovered that women were not mandated to participate in US clinical trials until 1993. She also experienced firsthand the limitations of existing cycle-tracking applications, which did not adequately represent her own irregular cycle patterns. This observation, combined with her co-founder Agarwal, led to Clair Health's formation in spring 2025 and the subsequent capital raise.
The funding round reflects strong institutional backing beyond Khosla Ventures, with participation from a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and investor Anne Wojcicki. Khosla Ventures' involvement carries particular weight given the firm's track record backing high-impact consumer and technology companies including DoorDash, Affirm, and Okta. The syndicate composition suggests confidence in both the market opportunity and the founding team's ability to execute a meaningful shift in how women's health data is monitored at scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.